Suramin Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Completed · Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Suramin may stop the growth of glioblastoma multiforme by stopping blood flow to the tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining suramin with radiation therapy may be a more effective treatment for glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of suramin plus radiation therapy in treating patients who have newly diagnosed glioblastoma multiforme.
Key facts
- Study ID
- NCT00004073
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 54
- Starts
- 1999-12-01
- Expected to finish
- 2004-06-01
- Last updated by the study team
- 2012-05-03
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States
- H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
- Emory University Hospital - Atlanta — Atlanta, Georgia, United States
- Johns Hopkins Oncology Center — Baltimore, Maryland, United States
- Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Comprehensive Cancer Center of Wake Forest University Baptist Medical Center — Winston-Salem, North Carolina, United States
- University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.